AFM-28
- Generic Name
- AFM-28
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT05817058
- Locations
- 🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇫🇷Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
🇩🇰Rigshospitalet, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath